# US 2006/0078991 A1 · Antibody composition-producing cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078991 A1
- Document ID: US20060078991A1
- Status: Published application
- Kind: A1
- Application number: 11/287,359
- Filed: 2005-11-28
- Published: 2006-04-13
- Earliest claimed: 2000-10-06
- Assignees: Kyowa Hakko Kogyo Co., Ltd.
- Inventors: Yutaka Kanda; Mitsuo Satoh; Kazuyasu Nakamura; Kazuhisa Uchida; Toyohide Shinkawa; Naoko Yamane; Emi Hosaka; Kazuya Yamano; Motoo Yamasaki; Nobuo Hanai
- Web page: https://patentgrep.com/patent/US20060078991A1

## CPC

- C12P 21/005: {Glycopeptides, glycoproteins}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- C07K 16/18: against material from animals or humans
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/2812: {against CD4}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2887: {against CD20}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/3084: {against tumour-associated gangliosides}
- C07K 16/32: against translation products of oncogenes
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12N 9/1051: {Hexosyltransferases (2.4.1)}
- C12N 9/90: Isomerases (5.)
- C12N 15/8245: {involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}
- C12N 15/8257: {for the production of primary gene products, e.g. pharmaceutical products, interferon}
- C12N 15/8258: {for the production of oral vaccines (antigens) or immunoglobulins}
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C12Y 204/01068: Glycoprotein 6-alpha-L-fucosyltransferase (2.4.1.68), i.e. FUT8
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

## Claims

### Claim 1

An isolated host cell which have low or no 1,6-fucosyltransferase activity for adding fucose to N-acetylglucosamine of a reducing reminus of N-glycoside-linked sugar chains by deleting the gene encoding α1,6-fucosyltransferase gene or by adding a mutation to said gene to reduce or eliminate the fucosyltranferase activity.

### Claim 2 (depends on 1)

The isolated host cell of claim 1, wherein said host cell is a CHO cell.

### Claim 3 (depends on 1)

The isolated host cell of claim 1, wherein said host cell is a NSO cell.

### Claim 4 (depends on 1)

The isolated host cell of claim 1, wherein said host cell is a SP2/0 cell.

### Claim 5 (depends on 1)

The isolated host cell of claim 1, wherein said host cell is a YB2/0 cell.

### Claim 6 (depends on 1)

The isolated host cell of claim 1, wherein said antibody molecule is an IgG antibody.
